Assessment of catechol induction and glucuronidation in rat liver microsomes

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1426-1433

  Elovaara, Eivor ^a   Mikkola, Jouni ^a   Luukkanen, Leena ^a,b   Antonio, Laurence ^c   Fournel Gigleux, Sylvie ^c   Burchell, Brian ^d   Magdalou, Jacques ^a,c   Taskinen, Jyrki ^b  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Biopôle de l Université de Lorraine   (France)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLCATECHOL; 4 NITROCATECHOL; ANTIOXIDANT; ANTIPARKINSON AGENT; AROCLOR 1254; CATECHOL; ENTACAPONE; PLANT EXTRACT; POLYCHLORINATED BIPHENYL; TOLCAPONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; ENZYME ACTIVITY; GLUCURONIDATION; LIVER MICROSOME; MALE; METABOLIC REGULATION; MICROSOME MEMBRANE; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PARKINSONISM; PRIORITY JOURNAL; RAT; RISK ASSESSMENT;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HEPATITIS, TOXIC; ISOENZYMES; LIVER FUNCTION TESTS; MALE; MICROSOMES, LIVER; NAPHTHOLS; POLYCHLORINATED BIPHENYLS; PYRENES; RATS; RATS, WISTAR;

ANIMALIA;

EID: 9444249993     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000992     Document Type: Article

References (40)

1. (ACGIH) American Conference of Governmental Industrial Hygienists (2001) Catechol. Documentation of the Threshold Limit Values for Chemical Substances, 7th ed. American Conference of Governmental Industrial Hygienists, Cincinnati, OH.
2. Antonio L, Grillasca JP, Taskinen J, Elovaara E, Burchell B, Piet MH, Ethell B, Ouzzine M, Foumel-Gigleux S, and Magdalou J (2002) Characterization of catechol glucuronidation in rat liver. Drug Metab Dispos 30:199-207.
3. Antonio L, Xu J, Little JM, Burchell B, Magdalou J, and Radominska-Pandya A (2003) Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9 and UGT2B7. Arch Biochem Biophys 411:251-261.
4. Bock KW, Gschaidmeier H, Heel H, Lehmkoster T, Munzel PA, and Bock-Hennig BS (1999) Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases (review). Drug Metab Rev 31(2):411-422.
5. Bock KW, Gschaidmeier H, Heel H, Lehmkoster T, Munzel PA. Raschko F, and Bock-Hennig B (1998) AH receptor-controlled transcriptional regulation and function of rat and human UDP-glucuronosyltransferase isoforms. Adv Enzyme Regul 38:207-222.
6. Bolton J (2002) Quinoids, quinoid radicals and phenoxyl radicals formed from estrogen and antiestrogens. Toxicology 177:55-65.
7. Brooks DJ (2004) Safety and tolerability of COMT inhibitors (review). Neurology 62 (Suppl 1):S39-S46.
8. Burchell B, Brierley CH, Monaghan CH, and Clarke DJ (1998) The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 42:335-338.
9. Burchell B, Brierley CH, and Ranee D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819-1831.
10. Carmella SG, La Voie EJ, and Hecht SS (1982) Quantitative analysis of catechol and 4-methylcatechol in human urine. Food Chem Toxicol 20:587-590.
11. Cavalieri EL, Rogan EG, and Chakravarti D (2002) Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism (review). Cell Mol Life Sci 59:665-681.
12. Clarke DJ and Burchell B (1994) The uridine diphosphate glucuronosyltransferase multigene family: function and regulation. Handb Exp Pharmacol 112:3-43.
13. Colic M and Pavelic K (2000) Molecular mechanisms of anticancer activity of natural dietetic products. J Mol Med 78:333-336.
14. (ECCLS) European Committee for Clinical Laboratory Standards (1988) The European Committee for Clinical Laboratory Standards (ECCLS) Document 3-4:34-69.
15. Haasio K, Nissinen E, Sopanen L, and Heinonen EH (2002) Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects. J Neural Transm 109:1391-1401.
16. IARC Working Group (1999) Re-evaluation of some organic chemicals, hydrazine and hydrogen peroxide. In IARC Monographs on the Evaluation of Carcinogeneic Risks to Humans. IARC Scientific Publications No. 71.
17. Jackson MR, Fournel-Gigleux S, Handing D, and Burchell B (1988) Examination of the substrate specificity of cloned rat kidney phenol UDP-glucuronyltransferase expressed in COS-7 cells. Mol Pharmacol 34:638-642.
18. Jorga K, Fotteler B, Heizmann P, and Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513-520.
19. Keski-Hynnilä H, Kurkela M, Elovaara E, Antonio L, Magdalou J, Luukkanen L, Taskinen J, and Kostiainen R (2002) Comparison of electro spray, atmospheric pressure chemical ionization, and atmospheric pressure photo ionization in the identification of apomorphine, dobutamine and entacapone phase II metabolites in biological samples. Anal Chem 74:3449-3457.
20. Kurth MC and Adler CH (1998) COMT inhibition: a new treatment strategy for Parkinson's disease (review). Neurology 50(Suppl 5):S3-S14.
21. Lautala P, Ethell BT, Taskinen J, and Burchell B (2000) The specificity of glucuronidatiori of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385-1389.
22. Lautala P, Kivimaa M, Salomies H, Elovaara E, and Taskinen J (1997) Glucuronidation of entacapone, nitecapone, tolcapone and some other nitrocatechols by rat liver microsomes. Pharm Res (NY) 14:1444-1448.
23. Lautala P, Ulmanen I, and Taskinen J (2001) Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase. Mol Pharmacol 59:393-402.
24. Lovern MR, Cole EC, and Schlosser PM (2001) A review of quantitative studies on benzene metabolism. Crit Rev Toxicol 31:285-311.
25. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
26. Luukkanen L, Elovaara E, Lautala P, Taskinen J, and Vainio H (1997) Characterization of 1-hydroxypyrene as a novel marker substrate of 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase(s). Pharmacol Toxicol 80:152-158.
27. Luukkanen L, Kilpeläinen I, Kangas H, Ottoila P, Elovaara E, and Taskinen J (1999) Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides. Bioconjug Chem 10:150-154.
28. Luukkanen L, Mikkola J, Forsman T, Taavitsainen P, Taskinen J, and Elovaara E (2001) Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7 and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metab Dispos 29:1096-1101.
29. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene super family: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
30. Männistö PT and Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors (review). Pharmacol Rev 51:593-628.
31. Oesch F, Arand M, Coughtrie MW, Burchell B, and Steinberg P (1992) The distribution of UDP-glucuronosyltransferases in rat liver parenchymal and nonparenchymal cells. Biochem Pharmacol 43:731-737.
32. Olanow CW and the Tasmar Advisory Panel (2000) Tolcapone and hepatotoxic effects. Arch Neurol 57:263-267.
33. Penning TM, Burczynski ME, Hung CF, McCoull KD, Palackal NT, and Tsuruda LS (1999) Dihydrodiol dehydrogenases and polycyclic aromatic hydrocarbon activation: generation of reactive and redox active o-quinones (review). Chem Res Toxicol 12:1-18.
34. Poewe W (2004) The role of COMT inhibition in the treatment of Parkinson's disease (review). Neurology 62(Suppl 1):S31-S38.
35. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, and Mackenzie PI (1999) Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31:817-899.
36. Safe SH (1994) Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses and implications for risk assessment. Crit Rev Toxicol 24:87-149.
37. Spahr L, Rubbia-Brandt L, Burkhard PR, Assal F, and Hadengue A (2000) Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig Dis Sci 45: 1881-1884.
38. Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, and Coughtrie MWH (2003) Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos 31:1187-1197.
39. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
40. Wikberg T, Vuorela A, Ottoila P, and Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92.